菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Your Partner for Fast, Accurate Biologic Analysis

Analytical testing is vital to the safety, compliance, and quality of your biologic product. With a global network of cutting-edge technology and deep scientific expertise, WuXi Biologics’ Analytical Sciences (AS) team delivers precise, actionable insights at every stage of development. Our AS team partners with you to tailor solutions that advance your therapeutic pipeline swiftly and confidently.

Whether you require bioassay development, product characterization, routine testing, or other types of analytical testing, our comprehensive services are available as part of an integrated program or standalone.

In addition, AS helps, along with our biologics Discovery R&D teams, to identify the final lead drug candidates by testing multiple candidates for quality, stability and developability/manufacturability, thus reducing the risks for the subsequent CMC development process. 

A typical developability study includes the following aspects: 

  • Prediction of high-risk PTMs
  • Titer level
  • Aggregation tendency
  • Thermal stability
  • High-concentration solubility and viscosity
  • Short-term stability (thermal, freeze-thaw, forced degradation)

Our highly experienced analytical team supports our CMC development services across all process development functional groups, and also supports the investigations of GMP manufacturing issues.

During development, a collection of compendial, physicochemical, biochemical and potency assays are carefully selected based on scientific consideration and the deep understanding of our platform processes and assays to monitor product quality attributes and support process development.

Our highly skilled experts from the Mass Spectrometry, Forensic Analysis and Bioassay Centers of Excellence (CoE) provide high-quality product characterization services for our customers.

We are capable of comprehensive product and reference standard characterization on the molecule’s biochemical, biophysical and biological characteristics.

For novel drugs, we can conduct head-to-head comparison on release and characterization test items between GMP and tox lots. For biosimilar drugs, we can perform extensive similarity assessment.

For late-stage projects, we offer detailed characterization services to gain more insights into the product, such as charge variants and isoforms observed in forced degradation studies.

Our AS team performs testing on non-clinical lot release and stability samples, while the GMP lot release and stability are performed by the quality control team.

We have a comprehensive mAb-based platform testing panel for lot release. A customized  release panel is also available based on specific requirements from different filing regions or product characteristics and for non-mAb products.

For each product, a specification will be established for GMP lot release, following phase-appropriate strategies. During early phase method development, specifications with relatively broad ranges will be established based on process development data, industrial experience and regulatory requirements. As the project enters a later phase, the specification can be narrowed based on statistical data from multiple GMP lots.

Reference standard (RS) release also follows a life-cycle management strategy, including protocol-driven RS generation, qualification and annual re-qualification, routine management, and the bridging of interim, primary and working reference standards.

We have a dedicated stability team to handle non-GMP and GMP  stability programs, adhering to the same set of management practices and high operational standards per SOPs and protocols. 

The stability program operates based on the agreed upon stability protocol. Its testing process is controlled by our LIMS, which covers stability program configuration, sample pulling schedule management, and sample and testing tracking.

We provide basic stability programs for long-term, accelerated and stressed conditions, with well-designed time points to span across a long timeframe for establishing product shelf-life. A customized program is also available to suit customer’s clinical study timeline and product quality monitoring purposes.

Our analytical team is dedicated to preparing a well-structured Quality section of the Common Technical Document (CTD) for applications that will be submitted to regulatory authorities. The data integrity verification process will be completed before the dossier is finalized.

  • Critical Quality Attribute (CQA) analysis and Forced Degradation Study (FDS) are conducted to ensure the design of regulatory compliant stability programs​
  • Assay qualification for in-process samples to support PC (Process Characterization) and PPQ (Process Performance Qualification) campaign
  • Transfer to Quality Control group for Assay Validation to support late phase and commercial products
  • Comparability studies ensure robust release assays used for clinical stage and PPQ product batches.
  • Process-specific HCP (Host Cell Protein) services along with fractionation and characterization analysis are available for product variants

We provide a comprehensive range of assays to detect process-related impurities. Listed below are examples of impurity detection assays previously developed and validated by the WuXi Biologics Process Related Impurity Detection Center of Excellence. This list is not all-inclusive of all assays developed by the Center of Excellence. Contact us to learn more.

Learn more about our services:

Analytical Techniques

WuXi Biologics brings globally recognized analytical capability to every stage of your project, driving high standards and efficiency. Routine testing forms the cornerstone of a robust biologics program. Evaluating a product’s safety, quality, and efficacy prevents potential problems that more specialized tests might miss.

Learn more about our Routine Analytical Testing Services.

  • Titer
  • SEC
  • CEX
  • RP & HIC
  • Polysorbate
  • Sialic acid
  • N-Glycan profiling
  • Peptide mapping
  • Caliper or CE-SDS (NR and R)
  • iCIEF
  • Appearance, Color, Clarity
  • pH, Osmolality
  • Extractable Volume
  • Protein Concentration (UV)
  • (Lyo) Moisture Content, Weight Variation, Reconstitution Time
  • (Sub) Visible Particles
  • (PFS) Force of Break-Loose & Glide, Activation, Override Push, Needle Shield Pull-off
  • (AI) Force of Cap Removal, Activation, Needle Override, Needle Extension, Dosing Time & Accuracy, Visual Defect
  • Residual HCP
  • Residual DNA
  • Residual Protein A
  • Western Blot
  • SDS-PAGE (NR and R)
  • Sterility & CCIT
  • Bioburden & Endotoxin
  • Microbial Challenge
  • Micro ID
  • Appearance
  • ID via FTIR
  • Melting point
  • Purity via LC and GC
  • Loss on drying (LOD)
  • Residue on ignition (ROI)
  • Metal by ICP-MS
  • Binding assays
    • ELISA
    • SPR
  • Cell-based Assays
    • Anti-proliferation
    • Cytokine release
    • Neutralization
    • Immunoregulatory
    • Cellular signaling/apoptosis/ killing
  • Enzymatic activity assay
  • Optical Microscopy
  • Infrared Spectroscopy
  • Raman
  • Scanning Electron Microscopy- Energy Dispersive X-ray Spectroscopy (SEM-EDS)
  • Primary Structure
    • Intact/Subunit level by LC-MS
    • Peptide Mapping by LC-MS/MS
  • Higher-order Structure
    • Far/Near UV-CD, FTIR, Fluorescence
    • EC by UV/RI & AAA
    • Free Sulfhydryl Analysis
  • Aggregates and Fragments
    • SEC-ΜALS
    • AUC
  • Particle Sizing
    • DLS
    • MFI
  • Thermal Stability
    • DSC
  • HCP-MS Analysis
  • Sequence Variant Analysis
  • Variant Analysis
    • 2D-LC-MS, CIEF-MS, CZE-MS, SEC-MS

Method Management

Following the unique properties of the molecule, WuXi Biologics Analytical Sciences (AS) team offers a full set of analytical methods leveraging physical-chemical, biological, higher-order structural, and protein structural analytical technologies. AS has extensive experiences in analytical method development for different types of proteins, including but not limited to monoclonal antibodies, fusion proteins, antibody drug conjugates (ADCs), recombinant proteins and bispecific antibodies.

For the DS/DP release assays, we provide analytical method qualification/validation following ICH Guideline Q2(R1), FDA Guidance for Industry, PDA Technical Report No. 57, and USP General Chapter <1225>&<1226>. Assays to be qualified/validated include product-specific methods, process-related methods and microbiological methods.

We offer method transfer services to the receiving lab for analytical methods including but not limited to in-process testing assays, DS & DP release assays and characterization assays.

With our comprehensive method lifecycle management, we optimize your biopharmaceutical development—ensuring efficiency and compliance from start to finish.

Related Resources

[Webinar] Advanced Analytical Strategies from Protein Structure Characterization to Potency Assessment for Challenging Biologic Modalities

View

[Webinar] Assessing Pharmacokinetics and Manufacturability in Early Biologics Drug Discovery

View

[Perspectives] Current Trends in Host Cell Protein Detection for Biologics Manufacturing

Read

[Article] Process Analytical Technology (PAT) for Lyophilization Process Monitoring and End Point Detection

Read

[Article] Complementary methods for monitoring hole-hole homodimer associated with a WuXiBody-based asymmetric bispecific antibody

Read

[Article] Monitoring removal of hole-hole homodimer by analytical hydrophobic interaction chromatography in purifying a bispecific antibody

Read

Connect with our Experts

Let’s discuss your project needs.
Contact Us